Navigation Links
Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
Date:11/1/2007

WALTHAM, Mass., Nov. 1 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, is presenting tomorrow at the Annual Meeting of the American Society of Nephrology an abstract entitled "Recombinant Human Elastase (PRT-201) Dilates Outflow Veins in a Preclinical Model of Arteriovenous Fistula." Findings to be presented represent an important preclinical demonstration of the potential of PRT-201 to enhance arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. It is well documented that between 30 and 50 percent of AVFs, the preferred form of vascular access, fail to mature to usable access sites for dialysis patients.

"Vascular access related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, the Company's President and CEO. "We believe that PRT-201 could potentially facilitate the creation of more reliable dialysis access sites."

About Vascular Access in Hemodialysis

Patients with end stage kidney disease must undergo periodic external blood filtering by hemodialysis machines in order to remove fluid and metabolic byproducts from their blood. Vascular surgeons prepare patients for hemodialysis by creating access sites in the body that can be connected to hemodialysis machines. These high flow access sites are usually created by connecting an artery to a vein, resulting in a "shunt" of blood from the artery to the vein. There are three main types of chronic hemodialysis access sites: Arteriovenous fistulas are created by connecting veins directly to arteries, arteriovenous grafts are created by connecting veins to arteries with a segment of artificial tubing, and catheters are placed directly in large vein
'/>"/>

SOURCE Proteon Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... N.Y., Dec. 15 On January 20th, ... Society for Medical Publication Professionals (ISMPP) will be ... London, UK. More than 100 attendees are expected ... for publication professionals, editors, publishers, medical writers and ... medical publications and the impact of guidelines and ...
(Date:12/15/2009)... Law Office has announced the launch of several innovative ... legal services in the current economic climate. The ... opportunity to finance legal services over a period of ... equity in their start-up companies. The second is ... montly payment arrangements over 6 to 12 month period ...
(Date:12/14/2009)... Dec. 14 Dyadic International, Inc. (Pink ... extended its collaboration with The Scripps Research Institute ... to re-annotate the genome of Dyadic,s patented and ... a continuation of the successful relationship between the ... Dyadic engaged Scripps to annotate the C1 genome ...
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
Breaking Biology Technology:Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3
... TEL AVIV, Israel, September 23 InspireMD, Ltd.,announced ... in its study of,MGuard(TM) coronary stent in acute ... Infarction Study) is designed to evaluate,the safety and ... myocardial infarction. The first 3 patients were implanted,successfully ...
... Identify Five Candida ... One Test, WOBURN, Mass., Sept. 23 ... the Yeast Traffic Light PNA FISH(TM) to,identify Candida ... Traffic Light(TM) is the latest addition to AdvanDx,s ...
... 23 Affitech AS, the Norwegian human,antibody ... accomplished the,second milestone in its research and ... recombinant antibodies against an unnamed oncology,target. Affitech ... Antibody,Screening) system that included its proprietary antibody ...
Other Biology Technology:InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2
(Date:12/15/2009)... brain diseases such as Alzheimer,s and Parkinson,s, doctors can ... help a patient. , But they come up empty-handed ... patients with ataxia disabling disorders that rob people ... neurologists are trying to change that with the help ... Institute of Neurological Disorders and Stroke to establish a ...
(Date:12/15/2009)... 15, 2009 Economics, environmental impacts, social dynamics, ... influence the overall success of an agroecosystem. Positive ... system, forcing individuals and social groups to continuously ... survive. , Experiential learning theory suggests that ... firsthand experiences. Such lessons are especially valuable for ...
(Date:12/15/2009)... VIB and Ghent University in Flanders, Belgium have found ... the major cause of death in intensive care units. ... in mice with septic shock, researchers Anje Cauwels and ... less damage, while their chances of survival increased significantly. ... assumed that nitric oxide is responsible for the potentially ...
Breaking Biology News(10 mins):UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3Experiential learning teaches change and adaptation 2Septic shock: Nitric oxide beneficial after all 2Schulman Associates IRB Establishes an Institutional Review Board in Canada 14618 1Schulman Associates IRB Establishes an Institutional Review Board in Canada 14618 2American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento 5753 1American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento 5753 2American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento 5753 3URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4
... -- As the first plant life to emerge from ... a unique opportunity for researchers to understand the development ... bryophites (liverworts, hornworts, and mosses) have long been utilized ... with the recent effects of climate change and the ...
... tumorsusing a safe minimally invasive interventional radiology treatment ... surgeryshould be the gold standard or first treatment ... 4 centimeters in size or smaller. And, this ... larger tumors, according to two studies presented at ...
... kind to evaluate the effect of red versus white wine ... it comes to increasing breast-cancer risk. The results of the ... were published in the March issue of Cancer Epidemiology, ... red wine,s effects on breast-cancer risk. There is reason to ...
Other Biology News:How increased UV exposure impacts plants 2Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors 2Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors 3Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors 4Red wine vs. white? It makes no difference when it comes to breast-cancer risk 2
NPT1 (M-19)...
XA7 B6...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
Biology Products: